As­traZeneca rais­es $200M from its lat­est as­set sale; Austin-based Lung Ther­a­peu­tics rais­es $14M in ven­ture cash

→  As­traZeneca has sold the rights to its mi­grane drug, Zomig for $200 mil­lion up­front and $102 mil­lion in mile­stones. Ger­many-based Grü­nen­thal will gain the rights to mar­ket and sell the drug out­side of Japan. The sale comes as the As­traZeneca is aim­ing to mount a come­back and re­fo­cus on on­col­o­gy, which it em­pha­sized at AS­CO last week­end. In the mean­time, the phar­ma gi­ant has been sell­ing off a string of non-core or dis­ap­point­ing ther­a­pies to raise cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER